7 citations
,
October 2024 in “Frontiers in Immunology” In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.
Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.
January 2024 in “International Journal of Molecular Sciences” This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.
April 2022 in “Biomedicine & Pharmacotherapy” This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.
57 citations
,
April 2009 in “Differentiation” This study demonstrates that SDF-1/CXCL12 and CXCR4 signaling play a crucial role in directing the migration and positioning of melanoblasts in mouse hair follicle formation.